Novos Agentes Redutores de Potássio na Abordagem da Hipercalémia na Doença Renal Crónica

Abstract

Introduction: Hyperkalemia is a common finding in patients with chronic kidney disease. However, current therapies for its chronic control have proven ineffective. This review examines the efficacy and safety of two new cation-exchange resins, Patiromer and Sodium Zirconium Cyclosilicate. Materials and Methods: A review of the existing literature to date was conducted and clinical trials for these two drugs were included, as well as systematic reviews and meta-analysis of potential interest. Results and Discussion: Five clinical trials were found for Patiromer and eight for Sodium zirconium cyclosilicate. Information on these drugs regarding their efficacy, tolerability and short- and long-term safety, the main adverse effects reported, and their effects in patients with chronic kidney disease or on renin-angiotensin-aldosterone system inhibitor therapy was commented on. Conclusion: Although the safety of these drugs needs further study, Patiromer and Sodium zirconium cyclosilicate exhibited consistent and clinically relevant reductions in serum potassium among at-risk patients with an adequate tolerability profile